Tscan Therapeutics Inc (TCRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tscan Therapeutics Inc (TCRX) has a cash flow conversion efficiency ratio of -0.399x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.54 Million) by net assets ($69.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Tscan Therapeutics Inc (TCRX) market capitalisation for the company's overall valuation and market capitalisation.
Tscan Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tscan Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tscan Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tscan Therapeutics Inc ranked by their cash flow conversion efficiency. See Tscan Therapeutics Inc (TCRX) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Skycorp Solar Group Limited Ordinary Shares
NASDAQ:PN
|
-0.035x |
|
Castec Korea Co Ltd
KQ:071850
|
0.104x |
|
Trimegah Karya Pratama Tbk PT
JK:UVCR
|
0.798x |
|
Przedsiebiorstwo Przemyslu Spozywczego PEPEES S.A.
WAR:PPS
|
0.120x |
|
Agricore CS Holdings Berhad
KLSE:0309
|
0.138x |
|
Bio-View Ltd
TA:BIOV
|
0.069x |
|
Central Motek Co Ltd
KO:308170
|
-0.028x |
|
Diagnos Laboratorium Utama PT Tbk
JK:DGNS
|
0.008x |
Annual Cash Flow Conversion Efficiency for Tscan Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tscan Therapeutics Inc from 2019 to 2025. View TCRX live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $123.12 Million | $-135.32 Million | -1.099x | -138.98% |
| 2024-12-31 | $240.97 Million | $-110.82 Million | -0.460x | -13.08% |
| 2023-12-31 | $150.87 Million | $-61.36 Million | -0.407x | +39.19% |
| 2022-12-31 | $99.43 Million | $-66.50 Million | -0.669x | -120.91% |
| 2021-12-31 | $160.78 Million | $-48.68 Million | -0.303x | -525.26% |
| 2020-12-31 | $-42.46 Million | $-3.02 Million | 0.071x | +124.19% |
| 2019-12-31 | $42.54 Million | $-12.52 Million | -0.294x | -- |
About Tscan Therapeutics Inc
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic… Read more